All press releases
-
Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio
-
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
-
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)
-
Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer
-
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany
-
Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy
-
World Premiere: Diaccurate reveals the mechanism of immune disablement in HIV infection